TrialSignal
Clinical trial intelligence report
A Multiple Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1403 in Participants With Type 2 Diabetes Mellitus
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT07242469-Jul 28, 2026
NCT ID
NCT07242469
Status
RECRUITING
Phase
PHASE1
Sponsor
Merck Sharp & Dohme LLC
Executive brief
Investment-Ready Snapshot
A Multiple Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1403 in Participants With Type 2 Diabetes Mellitus is a PHASE1 clinical asset sponsored by Merck Sharp & Dohme LLC in Diabetes Mellitus, Type 2. SEO and diligence focus: MK-1403 + additive coformulation, Placebo + additive coformulation, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT07242469
Indication
Diabetes Mellitus, Type 2
Modality
small molecule
Target
MK-1403 + additive coformulation, Placebo + additive coformulation
Intervention
MK-1403 + additive coformulation, Placebo + additive coformulation
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.